Metabolic dysregulation in myelodysplastic neoplasm: impact on pathogenesis and potential therapeutic targets.

Fiche publication

Date publication

décembre 2024

Journal

Medical oncology (Northwood, London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr GUIDEZ Fabien

Tous les auteurs :
Zhou H, Xiang W, Zhou G, Rodrigues-Lima F, Guidez F, Wang L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39644425

Résumé

Despite significant advancements in the research of the pathogenesis mechanisms of Myelodysplastic Neoplasm (MDS) in recent years, there are still many gaps to fill. The advancement of metabolomics studies has led to a research booming in clarifying the impact of metabolic abnormalities during the pathogenesis of MDS. The present review primarily focuses on the dysregulated metabolic pathways, exploring the influences on the pathogenesis of MDS and their roles during the course of the disease. Furthermore, we discuss the potential of relevant metabolic pathways as therapeutic targets, along with the latest metabolic-related treatment drugs and approaches.